Abstract: A sheet conveying device includes a conveyor, a sound collector, and circuitry. The conveyor conveys a sheet. The conveyor conveys a sheet in a sheet conveyance direction. The sound collector collects an operating sound generated by a conveyance of the sheet. The circuitry is to extract a feature amount of the operating sound collected by the sound collector, and determine, at different positions in the sheet conveyance direction based on the feature amount, whether an abnormal conveyance of the sheet occurs until the sheet is conveyed to a given position in the sheet conveyance direction.

Abstract: Disclosed are adeno-associated viral vectors and plasmids encoding the same. Also disclosed are methods of using adeno-associated viral vectors to deliver a protein of interest to the subject. The disclosed vectors have phenotypes including but not limited to increased retention in the blood of a subject, avoidance of the liver, and transduction of the brain and other tissues.

Abstract: Disclosed are methods for performing transcription-dependent directed evolution (TRADE) and novel AAV capsids selected using such methods.

Abstract: Disclosed are methods for performing transcription-dependent directed evolution (TRADE) and novel AAV capsids selected using such methods.

Abstract: Disclosed are methods for performing transcription-dependent directed evolution (TRADE) and novel AAV capsids selected using such methods. This disclosure also provides novel AAV capsid mutants. TRADE technology was used to identify novel AAV vectors that mediate neuronal transduction in the brain following intravenous administration. Application of TRADE in vivo resulted in the identification of new AAV capsids that can transduce neurons more efficiently and more specifically than AAV9 in the brain following administration of the new AAV capsids. The disclosed methods may be used to identify AAV capsids that target various cell populations.

Abstract: Disclosed are methods for performing transcription-dependent directed evolution (TRADE) and novel AAV capsids selected using such methods.

Abstract: Recombinant adeno associated viral vectors are disclosed. These include AAV8 or AAV9 derived vectors that include capsid proteins with mutations that confer upon the vector particular characteristics such as the ability to transduce or avoid (detarget) particular tissues, to be retained longer in the blood, or to be internalized in a cell without viral expression.

Abstract: Disclosed herein are methods of high-throughput mapping of viral neutralizing antibody epitopes. Also disclosed are in vitro immunoprecipitation-based adeno-associated virus Barcode-Seq-based methods of mapping viral neutralizing antibody epitopes. In some embodiments, a method of high-throughput mapping of viral NtAb conformational epitopes can be utilized, which may comprise HP scanning of mutant viral libraries, immunoprecipitation (IP), and/or next-generation sequencing (NGS) technology. In some embodiments, a method of identifying one or more dominant epitopes in a viral vector may comprise contacting a mutant capsid of a virus with serum from a subject previously exposed to the virus and immunoprecipitating serum immunoglobulins from the serum. In various embodiments, the viral vector may be an AAV vector.

Abstract: Disclosed herein are methods for delivering a composition comprising an adeno-associated virus (AAV) to one or more pancreatic cells in a subject. Also disclosed are adeno-associated viral vectors for use in these methods.

Abstract: The present disclosure relates to methods of producing monoclonal antibodies in animals. In particular, the disclosure provides a method of producing, in vivo, antibodies against viral capsids (VCs) derived from a non-enveloped virus (NEV). The method includes administering to a subject, by hydrodynamic-based transfection, a first set of genetic material encoding NEV structural proteins to induce the subject's intracellular translation and assembly of the proteins into viral capsids. The method also includes administering a second set of genetic material encoding NEV non-structural proteins to facilitate the intracellular assembly of the NEV structural proteins. Thus, this method may be used to produce subject-generated antibody-producing cells that secrete anti-VC antibodies that may be harvested and screened for monoclonal anti-VC antibodies.

Abstract: Disclosed is a method for separating a first member (1) and a second member (2) joined to each other comprising the steps of placing a clamp ring (14) on the surface of the first member, plunging a rotating probe (17) having a screw thread on a peripheral surface thereof into the surface of the first member through a through hole (10) of the clamp ring until a tip end of the probe reaches beyond an interface between the first member and the second member, the screw thread being directed so as to lift material of the bonded part away from the second member as a lifted part. The two members can be rejoined to each other by collapsing the lifted part into a bonded part once again by using a rotating probe and a clamp ring.

Abstract: Disclosed are methods for performing transcription-dependent directed evolution (TRADE) and novel AAV capsids selected using such methods.

Abstract: The present invention provides a new vector for gene therapy said vector being therapeutically very efficient, viral particles comprising said vector, compositions comprising said viral particle, uses thereof, methods for the preparation of the vector), and therapies using said vector.

Abstract: Disclosed are methods for performing transcription-dependent directed evolution (TRADE) and novel AAV capsids selected using such methods.

Abstract: Human anti-AAV capsid polyclonal antibody conformational epitopes including those of neutralizing antibodies are provided. The epitopes can be recognized by human anti-AAV2 or other AAV strain-derived capsid polyclonal antibodies. One or more of the epitopes may be mutated to form AAV2 and other AAV strain-derived capsids that can escape antibody neutralization. Methods of identifying human anti-AAV capsid polyclonal antibody conformational epitopes are also provided.

Abstract: Disclosed are host cells that have modulated DUB gene product activity and methods of using such host cells for increased AAV vector production yield. The disclosure also provides fusion proteins that comprise a DUB domain from a DUB gene product and a viral protein domain, and methods of increasing production of AAV vectors from a host cell that comprise expressing at least one of these fusion proteins in the host cell.

Abstract: Disclosed herein are methods of high-throughput mapping of viral neutralizing antibody epitopes. Also disclosed are in vitro immunoprecipitation-based adeno-associated virus Barcode-Seq-based methods of mapping viral neutralizing antibody epitopes. In some embodiments, a method of high-throughput mapping of viral NtAb conformational epitopes can be utilized, which may comprise HP scanning of mutant viral libraries, immunoprecipitation (IP), and/or next-generation sequencing (NGS) technology. In some embodiments, a method of identifying one or more dominant epitopes in a viral vector may comprise contacting a mutant capsid of a virus with serum from a subject previously exposed to the virus and immunoprecipitating serum immunoglobulins from the serum. In various embodiments, the viral vector may be an AAV vector.

Abstract: Disclosed herein are methods of high-throughput mapping of viral neutralizing antibody epitopes. Also disclosed are in vitro immunoprecipitation-based adenoassociated virus Barcode-Seq-based methods of mapping viral neutralizing antibody epitopes. In some embodiments, a method of high-throughput mapping of viral NtAb conformational epitopes can be utilized, which may comprise HP scanning of mutant viral libraries, immunoprecipitation (IP), and/or next-generation sequencing (NGS) technology. In some embodiments, a method of identifying one or more dominant epitopes in a viral vector may comprise contacting a mutant capsid of a virus with serum from a subject previously exposed to the virus and immunopredpitating serum immunoglobulins from the serum. In various embodiments, the viral vector may be an AAV vector.

Abstract: A bolt includes a head, and a shank connected to the head and having a screw portion and a leading end portion. The leading end portion of the shank includes a wall portion that defines a hole. The wall portion includes: a deformation portion configured to be plastically deformed by a torque from a fastening tool to be inserted in the hole; and a space forming portion configured to form a space between the space forming portion and the fastening tool. The blot is configured such that a maximum torque applied to the deformation portion in a process, in which a part of the deformation portion is plastically deformed by the torque from the fastening tool and is accommodated in the space and the fastening tool is placed in an idle rotation state, is configured to be set to be within a predetermined range.

Abstract: Disclosed are adeno-associated viral vectors and plasmids encoding the same. Also disclosed are methods of using adeno-associated viral vectors to deliver a protein of interest to the subject. The disclosed vectors have phenotypes including but not limited to increased retention in the blood of a subject, avoidance of the liver, and transduction of the brain and other tissues.